{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:20:20Z","timestamp":1787782820418,"version":"build-2784847793"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["MCB-2437713"],"award-info":[{"award-number":["MCB-2437713"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006734","name":"Princeton University","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100006734","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41429-026-00939-7","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:05:39Z","timestamp":1782975939000},"page":"564-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Macrolide antibiotic action, resistance, and tolerance, and approaches to improve their activity against Gram-negative bacteria"],"prefix":"10.1038","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1918-692X","authenticated-orcid":false,"given":"Umar A.","family":"Aulia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyi","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0970-2123","authenticated-orcid":false,"given":"Lily I.","family":"Kronenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashaly","family":"Soto-Echevarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5707-8894","authenticated-orcid":false,"given":"Mark P.","family":"Brynildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"939_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/BF00638597","volume":"37","author":"H Brockmann","year":"1950","unstructured":"Brockmann H, Henkel W. Pikromycin, Ein Neues Antibiotikum Aus Actinomyceten. Naturwissenschaften. 1950;37:138\u20139.","journal-title":"Naturwissenschaften"},{"key":"939_CR2","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1111\/bph.13936","volume":"174","author":"GP Dinos","year":"2017","unstructured":"Dinos GP. The macrolide antibiotic renaissance. Br J Pharm. 2017;174:2967\u201383.","journal-title":"Br J Pharm"},{"key":"939_CR3","first-page":"281","volume":"2","author":"JM McGuire","year":"1952","unstructured":"McGuire JM, et al. Ilotycin, a new antibiotic. Antibiot Chemother (Northfield). 1952;2:281\u20133.","journal-title":"Antibiot Chemother (Northfield)"},{"key":"939_CR4","doi-asserted-by":"crossref","unstructured":"Lenz, KD et al. Macrolides: from toxins to therapeutics. Toxins (Basel). 2021;13:347.","DOI":"10.3390\/toxins13050347"},{"key":"939_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1128\/AAC.33.9.1413","volume":"33","author":"HA Kirst","year":"1989","unstructured":"Kirst HA, Sides GD. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother. 1989;33:1413\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1128\/AAC.28.5.630","volume":"28","author":"IO Kibwage","year":"1985","unstructured":"Kibwage IO, et al. Antibacterial activities of erythromycin A, B, C, and S and some of their derivatives. Antimicrob Agents Chemother. 1985;28:630\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR7","unstructured":"The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list, https:\/\/www.who.int\/publications\/i\/item\/B09474."},{"key":"939_CR8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.tibs.2018.06.011","volume":"43","author":"N V\u00e1zquez-Laslop","year":"2018","unstructured":"V\u00e1zquez-Laslop N, Mankin AS. How macrolide antibiotics work. Trends Biochem Sci. 2018;43:668\u201384.","journal-title":"Trends Biochem Sci"},{"key":"939_CR9","doi-asserted-by":"crossref","unstructured":"Fyfe, C et al. Resistance to macrolide antibiotics in public health pathogens. Cold Spring Harb Perspect Med. 2016;6:a025395.","DOI":"10.1101\/cshperspect.a025395"},{"key":"939_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1128\/AAC.37.2.354","volume":"37","author":"M Vaara","year":"1993","unstructured":"Vaara M. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. Antimicrob Agents Chemother. 1993;37:354\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR11","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1021\/acs.accounts.1c00020","volume":"54","author":"AG Myers","year":"2021","unstructured":"Myers AG, Clark RB. Discovery of macrolide antibiotics effective against multi-drug resistant gram-negative pathogens. Acc Chem Res. 2021;54:1635\u201345.","journal-title":"Acc Chem Res"},{"key":"939_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1021\/cr030107f","volume":"105","author":"L Katz","year":"2005","unstructured":"Katz L, Ashley GW. Translation and protein synthesis: macrolides. Chem Rev. 2005;105:499\u2013528.","journal-title":"Chem Rev"},{"key":"939_CR13","doi-asserted-by":"crossref","unstructured":"Abe, M et al. Autoinducer analogs can provide bactericidal activity to macrolides in pseudomonas aeruginosa through antibiotic tolerance reduction. Antibiotics (Basel). 2021;11:10.","DOI":"10.3390\/antibiotics11010010"},{"key":"939_CR14","doi-asserted-by":"crossref","unstructured":"Lanni, A et al. Activity of Drug combinations against mycobacterium abscessus grown in aerobic and hypoxic conditions. Microorganisms. 2022;10:1421.","DOI":"10.3390\/microorganisms10071421"},{"key":"939_CR15","unstructured":"The WHO AWaRe (Access, Watch, Reserve) antibiotic book (2022), https:\/\/www.who.int\/publications\/i\/item\/9789240062382."},{"key":"939_CR16","unstructured":"National Institute of Health and Care Excellence, Pneumonia diagnosis and management (2025), https:\/\/www.nice.org.uk\/guidance\/ng250."},{"key":"939_CR17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2024.02.003","volume":"30","author":"L Moja","year":"2024","unstructured":"Moja L, et al. WHO\u2019s essential medicines and AWaRe: recommendations on first- and second-choice antibiotics for empiric treatment of clinical infections. Clin Microbiol Infect. 2024;30:S1\u2013S51. Suppl 2.","journal-title":"Clin Microbiol Infect"},{"key":"939_CR18","doi-asserted-by":"crossref","unstructured":"Berry, M. The macrolide antibiotics. Q Rev Chem Soc. 1963;17:343\u201361.","DOI":"10.1039\/qr9631700343"},{"key":"939_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ange.19570690109","volume":"69","author":"RB Woodward","year":"1957","unstructured":"Woodward RB. Struktur und Biogenese der Makrolide. Angew Chem. 1957;69:50\u201358.","journal-title":"Angew Chem"},{"key":"939_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/cber.19510840306","volume":"84","author":"H Brockmann","year":"1951","unstructured":"Brockmann H, Henkel W. Pikromycin, ein bitter schmeckendes Antibioticum aus Actinomyceten. Chem Ber. 1951;84:284\u20138.","journal-title":"Chem Ber"},{"key":"939_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1246\/bcsj.55.59","volume":"55","author":"A Furusaki","year":"1982","unstructured":"Furusaki A, et al. The crystal and molecular-structure of pikromycin. Bull Chem Soc Jpn. 1982;55:59\u201362.","journal-title":"Bull Chem Soc Jpn"},{"key":"939_CR22","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1021\/ja01019a055","volume":"90","author":"H Muxfeldt","year":"1968","unstructured":"Muxfeldt H, et al. The structure of pikromycin. J Am Chem Soc. 1968;90:4748\u20139.","journal-title":"J Am Chem Soc"},{"key":"939_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1039\/qr9581200093","volume":"12","author":"NG Brink","year":"1958","unstructured":"Brink NG, Harman RE. Chemistry of some newer antibiotics. Q Rev. 1958;12:93\u2013115.","journal-title":"Q Rev"},{"key":"939_CR24","unstructured":"Bunch RL, McGuire JM. Erythromycin, its salts and method of preparation, in: Office, U.S.P. (Ed.) 1953."},{"key":"939_CR25","doi-asserted-by":"crossref","unstructured":"Robertsen HL, Musiol-Kroll EM. Actinomycete-derived polyketides as a source of antibiotics and lead structures for the development of new antimicrobial drugs. Antibiotics-Basel. 2019;8.","DOI":"10.3390\/antibiotics8040157"},{"key":"939_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1056\/NEJM195208142470701","volume":"247","author":"TH Haight","year":"1952","unstructured":"Haight TH, Finland M. Laboratory and clinical studies on erythromycin. N Engl J Med. 1952;247:227\u201332.","journal-title":"N Engl J Med"},{"key":"939_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1099\/00207713-37-1-19","volume":"37","author":"DP Labeda","year":"1987","unstructured":"Labeda DP. Transfer of the type strain of streptomyces-erythraeus (Waksman 1923) Waksman and Henrici 1948 to the Genus Saccharopolyspora Lacey and Goodfellow 1975 as Saccharopolyspora-Erythraea Sp-Nov, and designation of a neotype strain for streptomyces-erythraeus. Int J Syst Bacteriol. 1987;37:19\u201322.","journal-title":"Int J Syst Bacteriol"},{"key":"939_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0040-4039(00)90018-2","volume":"11","author":"DR Harris","year":"1965","unstructured":"Harris DR, et al. The structure and stereochemistry of erythromycin A. Tetrahedron Lett. 1965;11:679\u201385.","journal-title":"Tetrahedron Lett"},{"key":"939_CR29","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.1021\/ja01579a059","volume":"79","author":"PF Wiley","year":"1957","unstructured":"Wiley PF, et al. Erythromycin. 10. Structure of erythromycin. J Am Chem Soc. 1957;79:6062\u201370.","journal-title":"J Am Chem Soc"},{"key":"939_CR30","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1021\/cr9600316","volume":"97","author":"J Staunton","year":"1997","unstructured":"Staunton J, Wilkinson B. Biosynthesis of erythromycin and rapamycin. Chem Rev. 1997;97:2611\u201330.","journal-title":"Chem Rev"},{"key":"939_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/nsb0296-188","volume":"3","author":"J Staunton","year":"1996","unstructured":"Staunton J, et al. Evidence for a double-helical structure for modular polyketide synthases. Nat Struct Biol. 1996;3:188\u201392.","journal-title":"Nat Struct Biol"},{"key":"939_CR32","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1039\/a909079g","volume":"18","author":"J Staunton","year":"2001","unstructured":"Staunton J, Weissman KJ. Polyketide biosynthesis: a millennium review. Nat Prod Rep. 2001;18:380\u2013416.","journal-title":"Nat Prod Rep"},{"key":"939_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1146\/annurev.biochem.76.053105.093515","volume":"76","author":"C Khosla","year":"2007","unstructured":"Khosla C, et al. Structure and mechanism of the 6-deoxyerythronolide B synthase. Annu Rev Biochem. 2007;76:195\u2013221.","journal-title":"Annu Rev Biochem"},{"key":"939_CR34","doi-asserted-by":"publisher","first-page":"14808","DOI":"10.1073\/pnas.011399198","volume":"98","author":"SC Tsai","year":"2001","unstructured":"Tsai SC, et al. Crystal structure of the macrocycle-forming thioesterase domain of the erythromycin polyketide synthase: versatility from a unique substrate channel. Proc Natl Acad Sci USA. 2001;98:14808\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"939_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1128\/jb.174.3.725-735.1992","volume":"174","author":"JF Andersen","year":"1992","unstructured":"Andersen JF, Hutchinson CR. Characterization of Saccharopolyspora erythraea cytochrome P-450 genes and enzymes, including 6-deoxyerythronolide B hydroxylase. J Bacteriol. 1992;174:725\u201335.","journal-title":"J Bacteriol"},{"key":"939_CR36","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1099\/00221287-143-10-3251","volume":"143","author":"RG Summers","year":"1997","unstructured":"Summers RG, et al. Sequencing and mutagenesis of genes from the erythromycin biosynthetic gene cluster of Saccharopolyspora erythraea that are involved in L-mycarose and D-desosamine production. Microbiol-Uk. 1997;143:3251\u201362.","journal-title":"Microbiol-Uk"},{"key":"939_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jmb.2011.10.036","volume":"415","author":"MC Moncrieffe","year":"2012","unstructured":"Moncrieffe MC, et al. Structure of the glycosyltransferase EryCIII in complex with its activating P450 homologue EryCII. J Mol Biol. 2012;415:92\u2013101.","journal-title":"J Mol Biol"},{"key":"939_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/cbic.200600509","volume":"8","author":"C Zhang","year":"2007","unstructured":"Zhang C, et al. The in vitro characterization of the erythronolide mycarosyltransferase EryBV and its utility in macrolide diversification. Chembiochem. 2007;8:385\u201390.","journal-title":"Chembiochem"},{"key":"939_CR39","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1021\/bi00006a006","volume":"34","author":"RH Lambalot","year":"1995","unstructured":"Lambalot RH, et al. Overproduction and characterization of the erythromycin C-12 hydroxylase, EryK. Biochemistry. 1995;34:1858\u201366.","journal-title":"Biochemistry"},{"key":"939_CR40","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1128\/jb.172.5.2541-2546.1990","volume":"172","author":"TJ Paulus","year":"1990","unstructured":"Paulus TJ, et al. Mutation and cloning of eryG, the structural gene for erythromycin O-methyltransferase from Saccharopolyspora erythraea, and expression of eryG in Escherichia coli. J Bacteriol. 1990;172:2541\u20136.","journal-title":"J Bacteriol"},{"key":"939_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1472-765X.2010.02973.x","volume":"52","author":"Q Zhang","year":"2011","unstructured":"Zhang Q, et al. Knocking out of tailoring genes in an industrial erythromycin-producing strain of Saccharopolyspora erythraea leading to overproduction of erythromycin B, C and D at different conversion ratios. Lett Appl Microbiol. 2011;52:129\u201337.","journal-title":"Lett Appl Microbiol"},{"key":"939_CR42","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00253-009-2326-8","volume":"85","author":"SR Park","year":"2010","unstructured":"Park SR, et al. Genetic engineering of macrolide biosynthesis: past advances, current state, and future prospects. Appl Microbiol Biotechnol. 2010;85:1227\u201339.","journal-title":"Appl Microbiol Biotechnol"},{"key":"939_CR43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/ja.2016.137","volume":"70","author":"P Fernandes","year":"2017","unstructured":"Fernandes P, et al. Nature nurtures the design of new semi-synthetic macrolide antibiotics. J Antibiot (Tokyo). 2017;70:527\u201333.","journal-title":"J Antibiot (Tokyo)"},{"key":"939_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jac\/25.suppl_A.39","volume":"25","author":"EF Fiese","year":"1990","unstructured":"Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother. 1990;25:39\u201347.","journal-title":"J Antimicrob Chemother"},{"key":"939_CR45","first-page":"148","volume":"4","author":"M Lebel","year":"1993","unstructured":"Lebel M. Pharmacokinetic properties of clarithromycin: A comparison with erythromycin and azithromycin. Can J Infect Dis. 1993;4:148\u201352.","journal-title":"Can J Infect Dis"},{"key":"939_CR46","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1021\/jo00245a038","volume":"53","author":"WR Baker","year":"1988","unstructured":"Baker WR, et al. Modification of macrolide antibiotics - synthesis of 11-deoxy-11-(carboxyamino)-6-O-methylerythromycin-a 11,12-(cyclic esters) via an intramolecular michael reaction of o-carbamates with an alpha,beta-unsaturated ketone. J Org Chem. 1988;53:2340\u20135.","journal-title":"J Org Chem"},{"key":"939_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1128\/AAC.33.1.78","volume":"33","author":"PB Fernandes","year":"1989","unstructured":"Fernandes PB, et al. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. Antimicrob Agents Chemother. 1989;33:78\u201381.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR48","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/jac\/41.6.649","volume":"41","author":"JM Hamilton-Miller","year":"1998","unstructured":"Hamilton-Miller JM, Shah S. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status. J Antimicrob Chemother. 1998;41:649\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"939_CR49","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/jac\/46.5.797","volume":"46","author":"H Okamoto","year":"2000","unstructured":"Okamoto H, et al. Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan. J Antimicrob Chemother. 2000;46:797\u2013802.","journal-title":"J Antimicrob Chemother"},{"key":"939_CR50","first-page":"153","volume":"1241","author":"RM Echols","year":"2011","unstructured":"Echols RM. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world. Antimicrobial Therapeutics Rev: Antibiotics That Target Ribosome. 2011;1241:153\u201361.","journal-title":"Antimicrobial Therapeutics Rev: Antibiotics That Target Ribosome"},{"key":"939_CR51","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMp078032","volume":"356","author":"DB Ross","year":"2007","unstructured":"Ross DB. The FDA and the case of Ketek. N Engl J Med. 2007;356:1601\u20134.","journal-title":"N Engl J Med"},{"key":"939_CR52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1473-3099(08)70002-1","volume":"8","author":"DM Shlaes","year":"2008","unstructured":"Shlaes DM, Moellering RC. Telithromycin and the FDA: implications for the future. Lancet Infect Dis. 2008;8:83\u20135.","journal-title":"Lancet Infect Dis"},{"key":"939_CR53","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMc076135","volume":"356","author":"J Soreth","year":"2007","unstructured":"Soreth J, et al. Ketek-the FDA perspective. N Engl J Med. 2007;356:1675\u20136.","journal-title":"N Engl J Med"},{"key":"939_CR54","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.1016\/j.bmc.2016.08.035","volume":"24","author":"P Fernandes","year":"2016","unstructured":"Fernandes P, et al. The solithromycin journey-It is all in the chemistry. Bioorg Med Chem. 2016;24:6420\u20138.","journal-title":"Bioorg Med Chem"},{"key":"939_CR55","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1128\/AAC.00860-10","volume":"54","author":"B Llano-Sotelo","year":"2010","unstructured":"Llano-Sotelo B, et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother. 2010;54:4961\u201370.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR56","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","volume":"16","author":"CM Barrera","year":"2016","unstructured":"Barrera CM, et al. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infect Dis. 2016;16:421\u201330.","journal-title":"Lancet Infect Dis"},{"key":"939_CR57","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/cid\/ciw490","volume":"63","author":"TM File Jr.","year":"2016","unstructured":"File TM Jr., et al. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis. 2016;63:1007\u201316.","journal-title":"Clin Infect Dis"},{"key":"939_CR58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt0317-187","volume":"35","author":"B Owens","year":"2017","unstructured":"Owens B. Solithromycin rejection chills antibiotic sector. Nat Biotechnol. 2017;35:187\u20138.","journal-title":"Nat Biotechnol"},{"key":"939_CR59","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S1473-3099(19)30116-1","volume":"19","author":"MY Chen","year":"2019","unstructured":"Chen MY, et al. Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trial. Lancet Infect Dis. 2019;19:833\u201342.","journal-title":"Lancet Infect Dis"},{"key":"939_CR60","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.anl.2023.11.008","volume":"51","author":"Y Kurono","year":"2024","unstructured":"Kurono Y, et al. Efficacy, safety, and tissue penetration of solithromycin in Japanese patients with otorhinolaryngological infections. Auris Nasus Larynx. 2024;51:379\u201390.","journal-title":"Auris Nasus Larynx"},{"key":"939_CR61","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s00044-024-03281-5","volume":"33","author":"S Bhawsar","year":"2024","unstructured":"Bhawsar S, et al. Nafithromycin (MIQNAF\u00ae): ultramodern lactone ketolide designed to treat community acquired bacterial pneumonia (CABP). Medicinal Chem Res. 2024;33:1715\u201333.","journal-title":"Medicinal Chem Res"},{"key":"939_CR62","unstructured":"Wockhardt Limited, Indian Drug Regulator Approves Wockhardt\u2019s New Generation Oral Antibiotic Miqnaf\u00ae (Nafithromycin) for the Treatment of Community Acquired Bacterial Pneumonia (CABP), 2025."},{"key":"939_CR63","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/0006-3002(59)90535-9","volume":"33","author":"TD Brock","year":"1959","unstructured":"Brock TD, Brock ML. Similarity in mode of action of chloramphenicol and erythromycin. Biochim Biophys Acta. 1959;33:274\u20135.","journal-title":"Biochim Biophys Acta"},{"key":"939_CR64","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0005-2787(66)90310-8","volume":"114","author":"D Vazquez","year":"1966","unstructured":"Vazquez D. Antibiotics affecting chloramphenicol uptake by bacteria. Their effect on amino acid incorporation in a cell-free system. Biochim Biophys Acta. 1966;114:289\u201395.","journal-title":"Biochim Biophys Acta"},{"key":"939_CR65","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1126\/science.143.3613.1445","volume":"143","author":"AD Wolfe","year":"1964","unstructured":"Wolfe AD, Hahn FE. Erythromycin: mode of action. Science. 1964;143:1445\u20136.","journal-title":"Science"},{"key":"939_CR66","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/0005-2787(66)90301-7","volume":"123","author":"SB Taubman","year":"1966","unstructured":"Taubman SB, et al. Sensitivity and resistance to erythromycin in Bacillus subtilis 168: the ribosomal binding of erythromycin and chloramphenicol. Biochim Biophys Acta. 1966;123:438\u201340.","journal-title":"Biochim Biophys Acta"},{"key":"939_CR67","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1021\/bi00719a029","volume":"13","author":"PC Tai","year":"1974","unstructured":"Tai PC, et al. Selective action of erythromycin on initiating ribosomes. Biochemistry. 1974;13:4653\u20139.","journal-title":"Biochemistry"},{"key":"939_CR68","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1021\/bi00787a014","volume":"10","author":"JC Mao","year":"1971","unstructured":"Mao JC, Robishaw EE. Effects of macrolides on peptide-bond formation and translocation. Biochemistry. 1971;10:2054\u201361.","journal-title":"Biochemistry"},{"key":"939_CR69","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1432-1033.1977.tb11422.x","volume":"74","author":"A Contreras","year":"1977","unstructured":"Contreras A, Vazquez D. Cooperative and antagonistic interactions of peptidyl-tRNA and antibiotics with bacterial ribosomes. Eur J Biochem. 1977;74:539\u201347.","journal-title":"Eur J Biochem"},{"key":"939_CR70","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1073\/pnas.72.7.2649","volume":"72","author":"T Otaka","year":"1975","unstructured":"Otaka T, Kaji A. Release of (oligo) peptidyl-tRNA from ribosomes by erythromycin A. Proc Natl Acad Sci USA. 1975;72:2649\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"key":"939_CR71","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1128\/AAC.21.5.811","volume":"21","author":"JR Menninger","year":"1982","unstructured":"Menninger JR, Otto DP. Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes. Antimicrob Agents Chemother. 1982;21:811\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR72","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/0300-9084(87)90218-5","volume":"69","author":"S Andersson","year":"1987","unstructured":"Andersson S, Kurland CG. Elongating ribosomes in vivo are refractory to erythromycin. Biochimie. 1987;69:901\u20134.","journal-title":"Biochimie"},{"key":"939_CR73","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/35101544","volume":"413","author":"F Schlunzen","year":"2001","unstructured":"Schlunzen F, et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001;413:814\u201321.","journal-title":"Nature"},{"key":"939_CR74","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0022-2836(03)00662-4","volume":"330","author":"T Tenson","year":"2003","unstructured":"Tenson T, et al. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003;330:1005\u201314.","journal-title":"J Mol Biol"},{"key":"939_CR75","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cell.2005.02.005","volume":"121","author":"D Tu","year":"2005","unstructured":"Tu D, et al. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell. 2005;121:257\u201370.","journal-title":"Cell"},{"key":"939_CR76","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.molcel.2010.12.031","volume":"41","author":"H Ramu","year":"2011","unstructured":"Ramu H, et al. Nascent peptide in the ribosome exit tunnel affects functional properties of the A-site of the peptidyl transferase center. Mol Cell. 2011;41:321\u201330.","journal-title":"Mol Cell"},{"key":"939_CR77","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.cell.2012.09.018","volume":"151","author":"K Kannan","year":"2012","unstructured":"Kannan K, et al. Selective protein synthesis by ribosomes with a drug-obstructed exit tunnel. Cell. 2012;151:508\u201320.","journal-title":"Cell"},{"key":"939_CR78","doi-asserted-by":"publisher","first-page":"15379","DOI":"10.1073\/pnas.1410356111","volume":"111","author":"AR Davis","year":"2014","unstructured":"Davis AR, et al. Sequence selectivity of macrolide-induced translational attenuation. Proc Natl Acad Sci USA. 2014;111:15379\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"939_CR79","doi-asserted-by":"publisher","first-page":"15958","DOI":"10.1073\/pnas.1417334111","volume":"111","author":"K Kannan","year":"2014","unstructured":"Kannan K, et al. The general mode of translation inhibition by macrolide antibiotics. Proc Natl Acad Sci USA. 2014;111:15958\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"939_CR80","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.celrep.2016.07.018","volume":"16","author":"S Sothiselvam","year":"2016","unstructured":"Sothiselvam S, et al. Binding of Macrolide Antibiotics Leads to Ribosomal Selection against Specific Substrates Based on Their Charge and Size. Cell Rep. 2016;16:1789\u201399.","journal-title":"Cell Rep"},{"key":"939_CR81","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/003693305600100701","volume":"1","author":"AF Maccabe","year":"1956","unstructured":"Maccabe AF, Gould JC. The epidemiology of an erythromycin resistant Staphylococcus. Scott Med J. 1956;1:223\u20136.","journal-title":"Scott Med J"},{"key":"939_CR82","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/archinte.1955.00250090057008","volume":"95","author":"RI Wise","year":"1955","unstructured":"Wise RI, et al. Origin of erythromycin-resistant strains of Micrococcus pyogenes in infections; bacteriophage types and in vitro resistance of cultures to antibiotics. AMA Arch Intern Med. 1955;95:419\u201326.","journal-title":"AMA Arch Intern Med"},{"key":"939_CR83","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41579-019-0196-3","volume":"17","author":"NQ Balaban","year":"2019","unstructured":"Balaban NQ, et al. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019;17:441\u20138.","journal-title":"Nat Rev Microbiol"},{"key":"939_CR84","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3389\/fmicb.2018.01942","volume":"9","author":"T Golkar","year":"2018","unstructured":"Golkar T, et al. Look and Outlook on Enzyme-Mediated Macrolide Resistance. Front Microbiol. 2018;9:1942.","journal-title":"Front Microbiol"},{"key":"939_CR85","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00452-24","volume":"68","author":"Y Ma","year":"2024","unstructured":"Ma Y, et al. The intrinsic macrolide resistome of Escherichia coli. Antimicrob Agents Chemother. 2024;68:e0045224.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR86","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/j.1365-2958.2007.05975.x","volume":"66","author":"S Zaman","year":"2007","unstructured":"Zaman S, et al. Novel mutations in ribosomal proteins L4 and L22 that confer erythromycin resistance in Escherichia coli. Mol Microbiol. 2007;66:1039\u201350.","journal-title":"Mol Microbiol"},{"key":"939_CR87","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1097-2765(01)00293-3","volume":"8","author":"IS Gabashvili","year":"2001","unstructured":"Gabashvili IS, et al. The polypeptide tunnel system in the ribosome and its gating in erythromycin resistance mutants of L4 and L22. Mol Cell. 2001;8:181\u20138.","journal-title":"Mol Cell"},{"key":"939_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.45.1.1-12.2001","volume":"45","author":"B Vester","year":"2001","unstructured":"Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother. 2001;45:1\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR89","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1128\/AAC.43.12.2823","volume":"43","author":"MC Roberts","year":"1999","unstructured":"Roberts MC, et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother. 1999;43:2823\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR90","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41589-020-00715-0","volume":"17","author":"MS Svetlov","year":"2021","unstructured":"Svetlov MS, et al. Structure of Erm-modified 70S ribosome reveals the mechanism of macrolide resistance. Nat Chem Biol. 2021;17:412\u201320.","journal-title":"Nat Chem Biol"},{"key":"939_CR91","doi-asserted-by":"crossref","unstructured":"Gupta, P et al. Deregulation of translation due to post-transcriptional modification of rRNA explains why genes are inducible. Nat Commun. 2013;4:1984.","DOI":"10.1038\/ncomms2984"},{"key":"939_CR92","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1365-2958.2008.06576.x","volume":"71","author":"H Ramu","year":"2009","unstructured":"Ramu H, et al. Programmed drug-dependent ribosome stalling. Mol Microbiol. 2009;71:811\u201324.","journal-title":"Mol Microbiol"},{"key":"939_CR93","doi-asserted-by":"publisher","first-page":"823","DOI":"10.7164\/antibiotics.41.823","volume":"41","author":"K O\u2019Hara","year":"1988","unstructured":"O\u2019Hara K, et al. Structure of a Phosphorylated Derivative of Oleandomycin, Obtained by Reaction of Oleandomycin with an Extract of an Erythromycin-Resistant Strain of Escherichia-Coli. J Antibiotics. 1988;41:823\u20137.","journal-title":"J Antibiotics"},{"key":"939_CR94","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.7164\/antibiotics.37.1692","volume":"37","author":"P Barthelemy","year":"1984","unstructured":"Barthelemy P, et al. Enzymic hydrolysis of erythromycin by a strain of Escherichia coli. A new mechanism of resistance. J Antibiot (Tokyo). 1984;37:1692\u20136.","journal-title":"J Antibiot (Tokyo)"},{"key":"939_CR95","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/j.1365-2958.1990.tb00696.x","volume":"4","author":"JI Ross","year":"1990","unstructured":"Ross JI, et al. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. Mol Microbiol. 1990;4:1207\u201314.","journal-title":"Mol Microbiol"},{"key":"939_CR96","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1046\/j.1365-2958.1996.01521.x","volume":"22","author":"J Clancy","year":"1996","unstructured":"Clancy J, et al. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol Microbiol. 1996;22:867\u201379.","journal-title":"Mol Microbiol"},{"key":"939_CR97","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1128\/AAC.00060-11","volume":"55","author":"ST Chancey","year":"2011","unstructured":"Chancey ST, et al. Induction of efflux-mediated macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2011;55:3413\u201322.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR98","doi-asserted-by":"publisher","first-page":"e0116254","DOI":"10.1371\/journal.pone.0116254","volume":"10","author":"ST Chancey","year":"2015","unstructured":"Chancey ST, et al. Transcriptional attenuation controls macrolide inducible efflux and resistance in Streptococcus pneumoniae and in other Gram-positive bacteria containing mef\/mel(msr(D)) elements. PLoS One. 2015;10:e0116254.","journal-title":"PLoS One"},{"key":"939_CR99","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0378-1119(94)00833-E","volume":"153","author":"JI Ross","year":"1995","unstructured":"Ross JI, et al. Identification of a chromosomally encoded ABC-transport system with which the staphylococcal erythromycin exporter MsrA may interact. Gene. 1995;153:93\u201398.","journal-title":"Gene"},{"key":"939_CR100","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.resmic.2012.12.003","volume":"164","author":"V Nunez-Samudio","year":"2013","unstructured":"Nunez-Samudio V, Chesneau O. Functional interplay between the ATP binding cassette Msr(D) protein and the membrane facilitator superfamily Mef(E) transporter for macrolide resistance in. Res Microbiol. 2013;164:226\u201335.","journal-title":"Res Microbiol"},{"key":"939_CR101","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bbrc.2004.01.044","volume":"315","author":"ID Kerr","year":"2004","unstructured":"Kerr ID. Sequence analysis of twin ATP binding cassette proteins involved in translational control, antibiotic resistance, and ribonuclease L inhibition. Biochem Biophys Res Commun. 2004;315:166\u201373.","journal-title":"Biochem Biophys Res Commun"},{"key":"939_CR102","doi-asserted-by":"crossref","unstructured":"Sharkey, LKR et al. ABC-F proteins mediate antibiotic resistance through ribosomal protection. Mbio. 2016;7:e01975.","DOI":"10.1128\/mBio.01975-15"},{"key":"939_CR103","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1073\/pnas.1803313115","volume":"115","author":"W Su","year":"2018","unstructured":"Su W, et al. Ribosome protection by antibiotic resistance ATP-binding cassette protein. Proc Natl Acad Sci USA. 2018;115:5157\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"939_CR104","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1128\/AAC.04468-14","volume":"59","author":"J Lenart","year":"2015","unstructured":"Lenart J, et al. Detailed mutational analysis of Vga(A) interdomain linker: implication for antibiotic resistance specificity and mechanism. Antimicrob Agents Chemother. 2015;59:1360\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR105","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41579-020-0386-z","volume":"18","author":"DN Wilson","year":"2020","unstructured":"Wilson DN, et al. Target protection as a key antibiotic resistance mechanism. Nat Rev Microbiol. 2020;18:637\u201348.","journal-title":"Nat Rev Microbiol"},{"key":"939_CR106","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41579-019-0218-1","volume":"17","author":"DI Andersson","year":"2019","unstructured":"Andersson DI, et al. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019;17:479\u201396.","journal-title":"Nat Rev Microbiol"},{"key":"939_CR107","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1128\/CMR.00058-14","volume":"28","author":"OM El-Halfawy","year":"2015","unstructured":"El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev. 2015;28:191\u2013207.","journal-title":"Clin Microbiol Rev"},{"key":"939_CR108","doi-asserted-by":"crossref","unstructured":"Band, VI et al. Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae. Nat Microbiol. 2016;1.","DOI":"10.1038\/nmicrobiol.2016.53"},{"key":"939_CR109","doi-asserted-by":"crossref","unstructured":"Band VI, Weiss DS Heteroresistance to beta-lactam antibiotics may often be a stage in the progression to antibiotic resistance. Plos Biol. 2021;19:e3001346.","DOI":"10.1371\/journal.pbio.3001346"},{"key":"939_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52166-z","volume":"15","author":"T Gil-Gil","year":"2024","unstructured":"Gil-Gil T, et al. The evolution of heteroresistance via small colony variants in Escherichia coli following long term exposure to bacteriostatic antibiotics. Nat Commun. 2024;15:7936.","journal-title":"Nat Commun"},{"key":"939_CR111","doi-asserted-by":"publisher","first-page":"e0131922","DOI":"10.1128\/aac.01319-22","volume":"67","author":"S Lohsen","year":"2023","unstructured":"Lohsen S, Stephens DS. Inducible mega-mediated macrolide resistance confers heteroresistance in streptococcus pneumoniae. Antimicrob Agents Chemother. 2023;67:e0131922.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR112","doi-asserted-by":"crossref","unstructured":"Lurchachaiwong, W et al. Determination of azithromycin heteroresistant Campylobacter jejuni in traveler\u2019s diarrhea. Gut Pathogens. 2019;11:19.","DOI":"10.1186\/s13099-019-0301-1"},{"key":"939_CR113","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2318600121","volume":"121","author":"BR Levin","year":"2024","unstructured":"Levin BR, et al. Theoretical considerations and empirical predictions of the pharmaco- and population dynamics of heteroresistance. Proc Natl Acad Sci USA. 2024;121:e2318600121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"939_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkae380","volume":"80","author":"A Ishak","year":"2025","unstructured":"Ishak A, et al. Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice. J Antimicrob Chemother. 2025;80:1\u201317.","journal-title":"J Antimicrob Chemother"},{"key":"939_CR115","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12014-019-9260-2","volume":"16","author":"R Rojony","year":"2019","unstructured":"Rojony R, et al. Quantitative analysis of Mycobacterium avium subsp. hominissuis proteome in response to antibiotics and during exposure to different environmental conditions. Clin Proteom. 2019;16:39.","journal-title":"Clin Proteom"},{"key":"939_CR116","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41429-021-00462-x","volume":"74","author":"RA Adams","year":"2021","unstructured":"Adams RA, et al. Rifamycin antibiotics and the mechanisms of their failure. J Antibiot (Tokyo). 2021;74:786\u201398.","journal-title":"J Antibiot (Tokyo)"},{"key":"939_CR117","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41429-023-00687-y","volume":"77","author":"AH Araten","year":"2024","unstructured":"Araten AH, et al. Cephalosporin resistance, tolerance, and approaches to improve their activities. J Antibiot (Tokyo). 2024;77:135\u201346.","journal-title":"J Antibiot (Tokyo)"},{"key":"939_CR118","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1128\/AAC.00739-06","volume":"51","author":"M Malik","year":"2007","unstructured":"Malik M, et al. Effect of anaerobic growth on quinolone lethality with Escherichia coli. Antimicrob Agents Chemother. 2007;51:28\u201334.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR119","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s44259-024-00042-7","volume":"2","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Transition metal homoeostasis is key to metabolism and drug tolerance of Mycobacterium abscessus. NPJ Antimicrob Resist. 2024;2:25.","journal-title":"NPJ Antimicrob Resist"},{"key":"939_CR120","doi-asserted-by":"publisher","first-page":"13673","DOI":"10.1073\/pnas.1717168115","volume":"114","author":"MS Svetlov","year":"2017","unstructured":"Svetlov MS, et al. Kinetics of drug-ribosome interactions defines the cidality of macrolide antibiotics. Proc Natl Acad Sci USA. 2017;114:13673\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"939_CR121","doi-asserted-by":"crossref","unstructured":"Chen, CW et al. Structural insights into the mechanism of overcoming Erm-mediated resistance by macrolides acting together with hygromycin-A. Nat Commun. 2023;14:4196.","DOI":"10.1038\/s41467-023-39653-5"},{"key":"939_CR122","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1073\/pnas.1918948117","volume":"117","author":"MS Svetlov","year":"2020","unstructured":"Svetlov MS, et al. A long-distance rRNA base pair impacts the ability of macrolide antibiotics to kill bacteria. Proc Natl Acad Sci USA. 2020;117:1971\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"939_CR123","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00246-21","volume":"9","author":"WM Matern","year":"2021","unstructured":"Matern WM, et al. Genetic determinants of intrinsic antibiotic tolerance in mycobacterium avium. Microbiol Spectr. 2021;9:e0024621.","journal-title":"Microbiol Spectr"},{"key":"939_CR124","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41429-021-00427-0","volume":"74","author":"H Ren","year":"2021","unstructured":"Ren H, et al. Synergistic bactericidal activities of tobramycin with ciprofloxacin and azithromycin against Klebsiella pneumoniae. J Antibiot (Tokyo). 2021;74:528\u201337.","journal-title":"J Antibiot (Tokyo)"},{"key":"939_CR125","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/B978-0-12-386497-0.00005-0","volume":"86","author":"BD Janssen","year":"2012","unstructured":"Janssen BD, Hayes CS. The tmRNA ribosome-rescue system. Adv Protein Chem Struct Biol. 2012;86:151\u201391.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"939_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15966-7","volume":"11","author":"F Peyrusson","year":"2020","unstructured":"Peyrusson F, et al. Intracellular Staphylococcus aureus persisters upon antibiotic exposure. Nat Commun. 2020;11:2200.","journal-title":"Nat Commun"},{"key":"939_CR127","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","volume":"17","author":"M Tyers","year":"2019","unstructured":"Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol. 2019;17:141\u201355.","journal-title":"Nat Rev Microbiol"},{"key":"939_CR128","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1128\/AAC.11.5.852","volume":"11","author":"C Reading","year":"1977","unstructured":"Reading C, Cole M. Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother. 1977;11:852\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR129","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd3801","volume":"11","author":"PY Muller","year":"2012","unstructured":"Muller PY, Milton MN. The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov. 2012;11:751\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"939_CR130","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1021\/acsinfecdis.7b00071","volume":"3","author":"RJ Melander","year":"2017","unstructured":"Melander RJ, Melander C. The challenge of overcoming antibiotic resistance: an adjuvant approach?. ACS Infect Dis. 2017;3:559\u201363.","journal-title":"ACS Infect Dis"},{"key":"939_CR131","doi-asserted-by":"crossref","unstructured":"Pham, VT et al. Preclinical pharmacokinetics and pharmacodynamics of antibiotic adjuvants. ACS Infect Dis. 2026;12:1794\u2013818.","DOI":"10.1021\/acsinfecdis.5c01065"},{"key":"939_CR132","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41429-022-00561-3","volume":"75","author":"S Chiu","year":"2022","unstructured":"Chiu S, et al. Causes of polymyxin treatment failure and new derivatives to fill the gap. J Antibiot (Tokyo). 2022;75:593\u2013609.","journal-title":"J Antibiot (Tokyo)"},{"key":"939_CR133","doi-asserted-by":"crossref","unstructured":"Ramirez, DM et al. Guanidinylated polymyxins as outer membrane permeabilizers capable of potentiating rifampicin, erythromycin, ceftazidime and aztreonam against gram-negative bacteria. Antibiotics-Basel. 2022;11:1277.","DOI":"10.3390\/antibiotics11101277"},{"key":"939_CR134","doi-asserted-by":"crossref","unstructured":"MacNair CR, Brown ED. Outer membrane disruption overcomes intrinsic, acquired, and spontaneous antibiotic resistance. mBio. 2020;11:e01615\u201320.","DOI":"10.1128\/mBio.01615-20"},{"key":"939_CR135","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1128\/AAC.01439-09","volume":"54","author":"M Vaara","year":"2010","unstructured":"Vaara M, et al. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrobial Agents Chemother. 2010;54:3341\u20136.","journal-title":"Antimicrobial Agents Chemother"},{"key":"939_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.858606","volume":"12","author":"P She","year":"2022","unstructured":"She P, et al. SPR741, double- or triple-combined with erythromycin and clarithromycin, combats drug-resistant klebsiella pneumoniae, its biofilms, and persister cells. Front Cell Infect Microbiol. 2022;12:858606.","journal-title":"Front Cell Infect Microbiol"},{"key":"939_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02875-z","volume":"9","author":"CR MacNair","year":"2018","unstructured":"MacNair CR, et al. Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat Commun. 2018;9:458.","journal-title":"Nat Commun"},{"key":"939_CR138","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ebiom.2015.05.021","volume":"2","author":"L Lin","year":"2015","unstructured":"Lin L, et al. Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant gram-negative bacterial pathogens. EBioMedicine. 2015;2:690\u20138.","journal-title":"EBioMedicine"},{"key":"939_CR139","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1021\/acsinfecdis.9b00067","volume":"5","author":"SE Martin","year":"2019","unstructured":"Martin SE, et al. Small molecule potentiation of gram-positive selective antibiotics against acinetobacter baumannii. ACS Infect Dis. 2019;5:1223\u201330.","journal-title":"ACS Infect Dis"},{"key":"939_CR140","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03084-21","volume":"13","author":"J Bailey","year":"2022","unstructured":"Bailey J, et al. Genetic dissection of antibiotic adjuvant activity. mBio. 2022;13:e0308421.","journal-title":"mBio"},{"key":"939_CR141","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1021\/acsmedchemlett.0c00276","volume":"11","author":"VB Hubble","year":"2020","unstructured":"Hubble VB, et al. Augmenting the activity of macrolide adjuvants against acinetobacter baumannii. ACS Med Chem Lett. 2020;11:1723\u201331.","journal-title":"ACS Med Chem Lett"},{"key":"939_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202400127","volume":"25","author":"AM Nemeth","year":"2024","unstructured":"Nemeth AM, et al. Identification of a 2-aminobenzimidazole scaffold that potentiates gram-positive selective antibiotics against gram-negative bacteria. Chembiochem. 2024;25:e202400127.","journal-title":"Chembiochem"},{"key":"939_CR143","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1021\/acsinfecdis.8b00288","volume":"5","author":"VB Hubble","year":"2019","unstructured":"Hubble VB, et al. Using small-molecule adjuvants to repurpose azithromycin for use against pseudomonas aeruginosa. ACS Infect Dis. 2019;5:141\u201351.","journal-title":"ACS Infect Dis"},{"key":"939_CR144","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1513\/AnnalsATS.201801-012OC","volume":"15","author":"JD Cogen","year":"2018","unstructured":"Cogen JD, et al. Chronic azithromycin use in cystic fibrosis and risk of treatment-emergent respiratory pathogens. Ann Am Thorac Soc. 2018;15:702\u20139.","journal-title":"Ann Am Thorac Soc"},{"key":"939_CR145","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fcimb.2019.00236","volume":"9","author":"KR Baker","year":"2019","unstructured":"Baker KR, et al. Repurposing azithromycin and rifampicin against gram-negative pathogens by combination with peptidomimetics. Front Cell Infect Microbiol. 2019;9:236.","journal-title":"Front Cell Infect Microbiol"},{"key":"939_CR146","doi-asserted-by":"publisher","first-page":"14937","DOI":"10.1021\/acs.jmedchem.0c01506","volume":"63","author":"S Hyun","year":"2020","unstructured":"Hyun S, et al. Proline hinged amphipathic alpha-helical peptide sensitizes gram-negative bacteria to various gram-positive antibiotics. J Med Chem. 2020;63:14937\u201350.","journal-title":"J Med Chem"},{"key":"939_CR147","doi-asserted-by":"crossref","unstructured":"Cui, ZH et al. Phentolamine significantly enhances macrolide antibiotic antibacterial activity against MDR gram-negative bacteria. Antibiotics-Basel. 2023;12:706.","DOI":"10.3390\/antibiotics12040760"},{"key":"939_CR148","doi-asserted-by":"crossref","unstructured":"Troudi, A et al. An original and efficient antibiotic adjuvant strategy to enhance the activity of macrolide antibiotics against gram-negative resistant strains. Int J Mol Sci. 2022;23:12457.","DOI":"10.3390\/ijms232012457"},{"key":"939_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17772-6","volume":"7","author":"C Muheim","year":"2017","unstructured":"Muheim C, et al. Increasing the permeability of Escherichia coli using MAC13243. Sci Rep. 2017;7:17629.","journal-title":"Sci Rep"},{"key":"939_CR150","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nchembio.221","volume":"5","author":"R Pathania","year":"2009","unstructured":"Pathania R, et al. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat Chem Biol. 2009;5:849\u201356.","journal-title":"Nat Chem Biol"},{"key":"939_CR151","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2402017122","volume":"122","author":"MW Tse","year":"2025","unstructured":"Tse MW, et al. Large-scale combination screens reveal small-molecule sensitization of antibiotic-resistant gram-negative ESKAPE pathogens. Proc Natl Acad Sci USA. 2025;122:e2402017122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"939_CR152","unstructured":"Centers for Disease Control and Prevention, Outpatient antibiotic prescriptions \u2014 United States (2022), https:\/\/archive.cdc.gov\/www_cdc_gov\/antibiotic-use\/data\/report-2022.html."},{"key":"939_CR153","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2002606","volume":"383","author":"T Doan","year":"2020","unstructured":"Doan T, et al. Macrolide and nonmacrolide resistance with mass azithromycin distribution. N Engl J Med. 2020;383:1941\u201350.","journal-title":"N Engl J Med"},{"key":"939_CR154","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S1473-3099(18)30444-4","volume":"19","author":"KS O\u2019Brien","year":"2019","unstructured":"O\u2019Brien KS, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis. 2019;19:e14\u2013e25.","journal-title":"Lancet Infect Dis"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00939-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:02:35Z","timestamp":1787781755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":154,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1038\/s41429-026-00939-7","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}